.Tarife

Consultatie oncologie medicala
590 lei
Control
400 lei

Program (20 - 24 Iulie)

Programează-te
Luni -
Marți -
Miercuri -
Joi -
Vineri -

Studii și experiență profesională

2019- Prezent Medic Primar – Oncologie Medicală, Institutul Sânului, Bucureşti
2018- Prezent Medic Primar – Oncologie Medicală Spitalul Medlife Titan Bucureşti
2012- 2018 Medic Primar – Oncologie Medicală Life Memorial Hospital Bucureşti
2008-2012 Medic Specialist – Oncologie Medicala Life Memorial Hospital Bucureşti
2007-2008 Medic Specialist – Oncologie Medicala Institutul Oncologic Bucuresti Bucureşti
2003-2007 Medic Rezident – Oncologie Medicala Institutul Oncologic Bucuresti Bucureşti
2002-2003 Medic Rezident – Medicina de Familie Spitalul Judeţean Brasov Brasov
2001 Absolventa a Facultaţii de Medicină Generală – Universitatea de Vest „ Vasile Goldis ” Arad
1994 Absolventa a Liceului Teoretic „Dinicu Golescu” Cimpulung

Cursuri postuniversitare

ESMO - 2-4 Apr 2004 Fundamentals in Medical Oncology ESMO 5x5x5 Educational Program - 30 Sep – 2 Oct 2004 Head and Neck, Thoracic Tumors ESMO 5x5x5 Educational Program - 23-25 Sep 2005 Gastrointestinals Tumors ESMO 5x5x5 Educational Program - 19-21 Apr 2007 Course on Molecular Targeted Therapy in Oncology: hopes, facts and further promises ESMO 5x5x5 Educational Program 10-12 Mai 2007 Palliative Care and Supportive Care in Medical Oncology Practice Traning ICH-GCP Noiembrie 2020

Evaluare profesionala la standarde europene

EUROPEAN CERTIFICATION IN MEDICAL ONCOLOGY- 23 Sept 2007 Barcelona, Spania EUROPEAN RECERTIFICATION APPROVAL IN MEDICAL ONCOLOGY- Nov 2012

Membru al asociaţiilor profesionale

Societatea Română de Oncologie Medicală din 2003 European Society of Medical Oncology (ESMO) din 2005 Balkan Union of Oncology (B.U.O.N.) din 2005 American Society of Clinical Oncology (ASCO) din 2006

Articole științifice

Chemotherapy for resectable non-small cell lung cancer. It’s time for a change in the current paradigm M.Dediu, Aurelia Alexandru, D.Median, Georgeta Vremes A Special edition of Journal of BUON 2005, Sept; 61- 88. ISSN 1107-0625.First Educational Course of BSO Volos, Greece, 16-17 Sep. 2005 Atelectasis as a good prognostic factor for advanced non-small cell lung cancer (NSCLC) M. Dediu, Rodica Anghel, D. Median, Aurelia Alexandru, D. Nuţu, A.Ţârlea, Anca Silaghi, Georgeta Vremeş, C.Gal, Loredana Nedeluş 31st ESMO Congress, Istanbul, Turkey, 29Sep – 03Oct 2006

Experiență studii clinice

Poziţie Aria terapeutică Indicatie Faza studiului
  Sub-investigator   removab vs. paracenteza   Ascita maligna   II / III
Sub-investigator Co-factor si 5 FU vs. LV si 5 FU Cancer de colon metastatic II B
Sub-investigator Bevacizumab si chimioterapie Cancer de colon metastatic IIIB
Sub-investigator Panitumumab+ FOLFIRI vs. FOLFIRI Cancer de colon metastatic III
Sub-investigator Chimioterapie +/-Bevacizumab Cancer de san metastatic III
Sub-investigator Topotecan vs. karenitecin Cancer ovarian avansat III
Sub-investigator   Chimioterapie + G-CSF Cancer de san metastatic III  
Sub-investigator Tapendadol vs. Morfina Durere III
Sub-investigator Chimioterapie+/- Sunitinib Cancer de san III
Principal- Investigator Chimioterapie+/- Rilotumumab Cancer gastric metastatic III